US · SERA · MEDICAL - DIAGNOSTICS & RESEARCH
Sera Prognostics, Inc. (SERA) intrinsic value and stock valuation
$1.81as of 2026-11-21 · Mkt cap 76.38M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Sera Prognostics, Inc. DCF and intrinsic value
InvestorsCraft values SERA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SERA’s statements →
Sera Prognostics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $80K | $80K | $310K | $270K | $80K |
| Operating income | -$-36.5M | -$-36.63M | -$-39.82M | -$-45.65M | -$-35.4M |
| Net income | -$-31.93M | -$-32.9M | -$-36.24M | -$-44.19M | -$-35.01M |
| EPSd | -$-669.95K | -$-992.16K | -$-1.16M | -$-1.43M | -$-1.14M |
| Operating cash flow | -$-25.62M | -$-14.19M | -$-27.19M | -$-34.61M | -$-31.64M |
| Capital expenditure | -$-730K | -$-1.1M | -$-130K | -$-790K | -$-1.3M |
| Free cash flow | -$-26.35M | -$-15.29M | -$-27.32M | -$-35.4M | -$-32.94M |
| Total assets | $101.9M | $72.6M | $95.4M | $116.3M | $147M |
| Total debt | $2.34M | $840K | $1.86M | $2.83M | $130K |
| Net debt | -$-1.6M | -$-3.2M | -$-2.02M | -$-27.05M | -$-58.8M |
| Total equity | $75.4M | $47.8M | $70.2M | $98.9M | $138.6M |
| Cash and short-term investments | $39.2M | $46.2M | $49.1M | $82.7M | $105.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $80K | $80K | $310K | $270K | $80K |
| Cost of revenue | $160K | $80K | $210K | $190K | $40K |
| Gross profit | -$-80K | -$-10K | $100K | $70K | $40K |
| Research and development expenses | $13.2M | $14.7M | $15.2M | $14.2M | $11M |
| Selling, general and administrative expenses | $23.3M | $21.9M | $24.7M | $31.5M | $24.4M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $36.4M | $36.6M | $39.9M | $45.7M | $35.4M |
| Cost and expenses | $36.6M | $36.7M | $40.1M | $45.9M | $35.5M |
| Interest income | $4.58M | $2.75M | $1.64M | $460K | $140K |
| Interest expense | $10K | $30K | $60K | $60K | $750K |
| Depreciation and amortization | $940K | $830K | $900K | $760K | $660K |
| Ebitda | -$-30.98M | -$-32.04M | -$-35.29M | -$-43.37M | -$-33.6M |
| Operating income | -$-36.5M | -$-36.63M | -$-39.82M | -$-45.65M | -$-35.4M |
| Total other income/expenses, net | $4.58M | $3.74M | $3.58M | $1.47M | $390K |
| Income before tax | -$-31.93M | -$-32.9M | -$-36.24M | -$-44.19M | -$-35.01M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-31.93M | -$-32.9M | -$-36.24M | -$-44.19M | -$-35.01M |
| Weighted average shares outstanding | $47.7M | $33.2M | $31.2M | $30.9M | $30.8M |
| Weighted average diluted shares outstanding | $47.7M | $33.2M | $31.2M | $30.9M | $30.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $39.2M | $46.2M | $49.1M | $82.7M | $105.1M |
| Net receivables | $10K | $30K | $11.5M | $6.11M | $3.14M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $40.8M | $47.6M | $61.3M | $90.1M | $110.3M |
| Property, plant and equipment, net | $3.55M | $1.85M | $3.18M | $3.06M | $1.77M |
| Goodwill and intangible assets | $910K | $1.03M | $0.00 | $0.00 | $0.00 |
| Long-term investments | $56.6M | $22M | $30.8M | $21.3M | $34.9M |
| Total non-current assets | $61.2M | $25M | $34.1M | $26.2M | $36.8M |
| Total assets | $101.9M | $72.6M | $95.4M | $116.3M | $147M |
| Accounts payable | $860K | $1.97M | $1.05M | $1.55M | $1.2M |
| Short-term debt | $0.00 | $840K | $1.02M | $980K | $70K |
| Deferred revenue | $20.3M | $20.2M | $20.2M | $9.08M | $3.12M |
| Total current liabilities | $24.2M | $24.8M | $24.4M | $15.5M | $8.41M |
| Long-term debt | $2.34M | $0.00 | $840K | $1.85M | $50K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $2.34M | $0.00 | $840K | $1.85M | $50K |
| Capital lease obligations | $2.34M | $840K | $1.86M | $2.83M | $130K |
| Total liabilities | $26.5M | $24.8M | $25.3M | $17.4M | $8.46M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-311.72M | -$-279.79M | -$-246.9M | -$-210.65M | -$-166.47M |
| Accumulated other comprehensive income (loss) | $260K | $60K | -$-10K | -$-980K | -$-180K |
| Total equity | $75.4M | $47.8M | $70.2M | $98.9M | $138.6M |
| Total investments | $91.8M | $64.2M | $76M | $74.2M | $81M |
| Total debt | $2.34M | $840K | $1.86M | $2.83M | $130K |
| Net debt | -$-1.6M | -$-3.2M | -$-2.02M | -$-27.05M | -$-58.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-31.93M | -$-32.9M | -$-36.24M | -$-44.19M | -$-35.01M |
| Depreciation and amortization | $940K | $830K | $900K | $760K | $660K |
| Stock-based compensation | $5.11M | $7.01M | $5.27M | $5.05M | $3.13M |
| Change in working capital | -$-550K | $11.3M | $3.52M | $3.55M | -$-40K |
| Accounts receivable | $20K | $11.4M | -$-5.36M | -$-2.97M | -$-3.14M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-1.01M | $460K | -$-440K | $350K | $600K |
| Net cash provided by operating activities | -$-25.62M | -$-14.19M | -$-27.19M | -$-34.61M | -$-31.64M |
| Investments in property, plant and equipment | -$-730K | -$-60K | -$-130K | -$-790K | -$-1.3M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-28.5M | $11.7M | $440K | $5.55M | -$-82.56M |
| Common stock issued | $54.2M | $0.00 | $0.00 | $0.00 | $66.6M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $54M | $2.61M | $750K | $10K | $159.6M |
| Net change in cash | -$-100K | $160K | -$-26M | -$-29.05M | $45.4M |
| Cash at end of period | $3.94M | $4.04M | $3.88M | $29.9M | $58.9M |
| Operating cash flow | -$-25.62M | -$-14.19M | -$-27.19M | -$-34.61M | -$-31.64M |
| Capital expenditure | -$-730K | -$-1.1M | -$-130K | -$-790K | -$-1.3M |
| Free cash flow | -$-26.35M | -$-15.29M | -$-27.32M | -$-35.4M | -$-32.94M |
Line items
Line items
Line items
About Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
- CEO
- Zhenya Lindgardt
- Employees
- 63
- Beta
- 0.97
Explore
Frequently asked questions
What is the intrinsic value of Sera Prognostics, Inc. (SERA)?
Sera Prognostics, Inc. (SERA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SERA undervalued?
SERA trades at a price of $1.81 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.